

South Dakota Department of Social Services, Division of Medicaid Services Pharmacy & Therapeutics (P&T) Committee Meeting Minutes

Friday, December 2, 2022

1:00 – 3:00 pm CT

Members and DSS Staff

Michelle Baack, MD	X	Heather Preuss, MD	X
Dana Darger, RPh, Chair	X	Matthew Stanley, DO	X
Mikel Holland, MD	X	Deidre Van Gilder, PharmD	X
Bill Ladwig, RPh	X	Mike Jockheck, DSS Staff	X
Kelley Oehlke, PharmD	X	Matthew Ballard, DSS Staff	X
Lenny Petrik, PharmD		Sarah Aker, DSS Staff	

Administrative Business

Darger called the meeting to order at 1:02 pm. The minutes of the September meeting were presented. Ladwig made a motion to approve. Holland seconded the motion. The motion was unanimously approved.

Biosimilar presentation

Mike Einodshoder, Chief Pharmacy Officer from OptumRx, provided an in-depth presentation on biosimilars.

Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity report from July 1, 2022, to September 30, 2022. A total of 1,852 PAs were reviewed of which 117 requests (6.3%) were received via telephone and 1,031 requests (55.7%) were received via fax, and 704 (38%) were reviewed via electronically. There was a 3.4% increase of PAs received compared to the previous quarter. Baack inquired if there were any cost savings from dermatological PA changes made the previous year.

Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from July 1, 2022, to September 30, 2022. The top five therapeutic classes based on paid amount were atypical antipsychotics, disease-modifying anti-rheumatic agents, skin and mucous membrane agents, cystic fibrosis correctors, and amphetamines. These top 15 therapeutic classes make up 25.27 % of total claims. The committee also reviewed the top 50 drugs based on amount paid and number of claims. The top 50 drugs by amount paid make up 9.64% of total claims. Darger commented on the increase of mupirocin claims during this quarter. A more in-depth analysis was requested which would be aligned with the dermatological PA reviews. The increase of epinephrine paid amount was also discussed. Van Gilder added that the increase may be due to the start of the school year. Past third quarter trends will be reviewed to confirm epinephrine increase. Darger inquired if there was any public comment. There was none.

Old Business

Narrow Therapeutic Index Drugs

The committee reviewed the NTI utilization of claims with DAW 1. Baack made a motion to remove the NTI list. Van Gilder seconded the motion. Darger inquired if there was any public comment. There was none. The motion was approved unanimously. Committee discussed pros and cons to adding electronic

PA to levothyroxine capsules. Baack made another motion to add manual review PA to levothyroxine capsules with no grandfathering. Van Gilder seconded the motion. Darger inquired if there was any public comment. There was none. The motion was approved unanimously.

Performance Measures

Samantha Moon from the Department of Medical Services provided follow up on two Performance Measures that the State is tracking: Follow up Care for Children Prescribed ADHD Medication; Ages 6-12 years old and Metabolic Monitoring for Children and Adolescents on Antipsychotics; Ages 1-17 years old. Baack questioned the lab tests included in the lipid panel. Moon will send list included in the lab tests. Stanley provided insight on antipsychotics prescribed in hospital settings and metabolic testing performed there. A new measure to the CORE Set is the Avoidance of Antibiotic Treatment for Acute Bronchitis which Moon will be presenting in the future.

Opioid update

The committee reviewed 3Q2022 opioid outcomes compared to previous quarters from the opioid initiatives. The opioid figures for 2Q2022 excluded IHS utilization with the last similar comparison during 4Q2019. There was an increase in opioid utilization and utilizers during 2Q2022 with corresponding increase in total eligibility and utilizers. Darger inquired if there was any public comment. There was none.

Adjournment

The next meeting scheduled on March 24, 2023. The June meeting is tentatively scheduled for June 9, 2023. The Committee made a motion to adjourn the meeting, and everyone seconded the motion. The motion passed unanimously, and the meeting adjourned at 2:58 pm.